Exhibit 1.01
Revvity, Inc.
Conflict
Minerals Report
For the Year Ended December 31, 2023
Overview
Revvity, Inc. (Revvity or
the Company), is filing this Conflict Minerals Report (Report) pursuant to Rule 13p-1 and Form SD under the Securities Exchange Act of 1934 (the Rule), for the reporting
period January 1, 2023 through December 31, 2023. The Rule requires companies that report under the Exchange Act to provide disclosures about conflict minerals that are necessary to the functionality or production of products that they
manufacture or contract to be manufactured. When those conflict minerals originate (or may have originated) in the Democratic Republic of the Congo or certain adjoining countries (the Covered Countries) and did not originate (or may not
have originated) from recycled or scrap sources, the Company must file a Conflict Minerals Report. Conflict Minerals are defined as cassiterite, columbite-tantalite (coltan), gold, wolframite, certain of their derivatives and other
minerals, including tungsten, tin and tantalum.
Revvity provides health science solutions, technologies, expertise and services that deliver complete
workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing whats possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction,
screening, detection and diagnosis, informatics and more. The Company was founded in 1947 and is headquartered in Waltham, Massachusetts. The Company reported revenues of more than $2.7 billion in 2023, serves customers in more than 190
countries, and employs more than 11,000 employees. Revvitys common stock is listed on the New York Stock Exchange under the symbol RVTY and we are a component of the S&P 500 Index.
We report our business in two segments: Life Sciences and Diagnostics:
Life Sciences. Our comprehensive portfolio of technologies helps life sciences researchers better understand diseases and develop
treatments. We provide a broad suite of products, solutions and services that facilitate optimized workflows, increase productivity, and accelerate every stage of the drug discovery and development pipeline. Our offerings span the areas of cell,
gene, and protein research, enabling scientists to work smarter, make research breakthroughs, and transform those breakthroughs into real-world outcomes. We partner with global pharmaceutical, biotech and contract research organizations, as well as
academic institutions, to enable them to discover and develop better treatments and therapeutics to fight disease faster and more efficiently.
Diagnostics. We offer instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical
research professionals to help improve the health of families. Our Diagnostics segment is especially focused on reproductive health, immunodiagnostics, emerging market diagnostics and applied genomics.
We provide early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market.
Our screening products are designed to provide early and accurate insights into the health of expectant mothers during pregnancy and into the health of their babies. Diagnostic labs use our instruments, reagents and software for testing and
screening genetic abnormalities and certain disorders and diseases, including Down syndrome, hypothyroidism, muscular dystrophy, infertility and various metabolic conditions. We also develop technologies that enable and support genomic workflows
using PCR and next-generation DNA sequencing for applications in oncology, immunodiagnostics and drug discovery.
1